Department of Medicine, University of California, San Diego, CA, USA.
Nat Rev Drug Discov. 2023 Apr;22(4):273-294. doi: 10.1038/s41573-022-00618-w. Epub 2023 Jan 24.
Protein phosphatases act as key regulators of multiple important cellular processes and are attractive therapeutic targets for various diseases. Although extensive effort has been dedicated to phosphatase-targeted drug discovery, early expeditions for competitive phosphatase inhibitors were plagued by druggability issues, leading to the stigmatization of phosphatases as difficult targets. Despite challenges, persistent efforts have led to the identification of several drug-like, non-competitive modulators of some of these enzymes - including SH2 domain-containing protein tyrosine phosphatase 2, protein tyrosine phosphatase 1B, vascular endothelial protein tyrosine phosphatase and protein phosphatase 1 - reigniting interest in therapeutic targeting of phosphatases. Here, we discuss recent progress in phosphatase drug discovery, with emphasis on the development of selective modulators that exhibit biological activity. The roles and regulation of protein phosphatases in immune cells and their potential as powerful targets for immuno-oncology and autoimmunity indications are assessed.
蛋白磷酸酶作为多种重要细胞过程的关键调节剂,是各种疾病有吸引力的治疗靶点。尽管人们已经投入了大量的精力用于磷酸酶靶向药物的发现,但早期针对竞争性磷酸酶抑制剂的探索受到了成药性问题的困扰,导致磷酸酶被污名化为难以成药的靶点。尽管存在挑战,但持续的努力已经导致了一些具有药物样性质的、非竞争性的这些酶的调节剂的鉴定,包括含 SH2 结构域的蛋白酪氨酸磷酸酶 2、蛋白酪氨酸磷酸酶 1B、血管内皮蛋白酪氨酸磷酸酶和蛋白磷酸酶 1,这重新激发了人们对磷酸酶治疗靶点的兴趣。在这里,我们讨论了磷酸酶药物发现的最新进展,重点介绍了具有生物活性的选择性调节剂的开发。评估了蛋白磷酸酶在免疫细胞中的作用和调节及其作为免疫肿瘤学和自身免疫疾病靶点的潜力。
Nat Rev Drug Discov. 2023-4
Anticancer Agents Med Chem. 2009-2
Annu Rev Immunol. 2008
Semin Immunol. 2006-8
Trends Pharmacol Sci. 2017-6
Curr Opin Chem Biol. 1998-10
Curr Opin Chem Biol. 2009-6
Acta Pharmacol Sin. 2014-10
Acta Pharmacol Sin. 2025-5-8
Cell Insight. 2025-4-10
Cancer Discov. 2022-3-1
J Clin Med. 2021-10-21
JCI Insight. 2021-10-22
J Immunol. 2021-9-15
J Clin Invest. 2021-7-20
Int J Mol Sci. 2021-4-10